https://hsp-signal.com/index.p....hp/igg4-related-stom
The discerning Bcl-2 inhibitor venetoclax (ABT-199) in combo treatment has been authorized to treat newly diagnosed AML patients who are ineligible for intensive chemotherapy, but resistance can be acquired through the upregulation of alternative antiapoptotic proteins. Here, we reported that a newly emerged histone deacetylase inhibitor, chidamide (CS055), at low-cytotoxicity dose improved the anti-AML activity of ABT-199, while sparing regu
Like
Comment
Share
